|
Jeffrey S. Clark, M.D.
Technology Specialist
Boston
As a Technology Specialist with Foley Hoag's Intellectual Property practice, Dr. Jeffrey Clark prosecutes patent applications in the fields of medicine, medical devices, molecular biology, biotechnology, and pharmaceuticals. His patent prosecution work in these areas reflects his extensive medical and life sciences research experience.
For three years prior to joining Foley Hoag in 2007, Jeff was a Research Fellow in Medicine at Harvard Medical School in the Molecular & Vascular Medicine Unit, Renal Division, Department of Medicine, Beth Israel Deaconess Medical Center. During his fellowship, he studied the structure/function relationship of orthologous SLC26 multifunctional anion exchangers. He also investigated SLC26A6 mediated oxalate transport, its regulatory mechanisms, and its role in nephrocalcinosis and nephrolithiasis pathogenesis.
Between his second and third year of medical school, Jeff worked at Harvard Medical School as an Honors Student Fellow in the Cardiovascular Research Center, Department of Cardiology, Massachusetts General Hospital. His research there involved investigating the role of nitric oxide synthase isoforms in ischemic preconditioning, myocardial infarction, stroke, and atherosclerosis using mouse models for these disease conditions.
In addition to his work at Harvard, Jeff has held numerous science and medical research internships and fellowships at Strong Memorial Hospital (University of Rochester Medical Center), Genetics Institute (now Wyeth Pharmaceuticals), Massachusetts General Hospital (Department of Pathology), the University of California at Berkeley (Department of Chemistry), and Brigham and Women's Hospital (Department of Endocrinology).
SPEECHES AND CONFERENCES
Selected speaker at the American Society of Nephrology (ASN) annual Renal Week 2006 Conference, "SLC26A6 transmembrane domain determines species-specific anion selectivity and electrogenecity," San Diego, CA
publications
Clark JS, Vandorpe DH, Chernova MN, Heneghan JF, Stewart AK, Alper SL, Species differences in Cl- affinity and in electrogenicity of SLC26A6-mediated oxalate/Cl- exchange correlate with the distinct human and mouse susceptibilities to nephrolithiasis, J. Physiol. (Epub 2008 Jan 3)
Zolotarev AS, Unnikrishnan M, Shmukler BE, Clark JS, Vandorpe DH, Grigorieff N, Rubin EJ, Alper SL, Increased sulfate uptake by E. coli overexpressing the SLC26-related SulP protein Rv1739c from M. tuberculosis, Comp. Biochem. and Physio. B (In press, 2008)
Shmukler BE, Clark JS, Hsu A, Vandorpe DH, Stewart AK, Kurschat CE, Ackermann GE, Zhou Y, Paw BH, Alper SL, Zebrafish AE2.2 encodes a second slc4a2 anion exchanger, Am J Physiol Reg. Int. and Comp. Physio. (Epub 2007 Nov 28)
Alper SL, Sewart AK, Chernova MN, Zolotarev AS, Clark JS, Vandorpe DH., Anion exchangers in flux: functional differences between human and mouse SLC26A6 polypeptides, Novartis Found Symp. 273; 107-29, 261-4 (2006)
Chernova, MN, Vandorpe, DH, Clark, JS, Williams, JI, Zasloff, MA, Jiang, L, Alper, SL., Apparent receptor-mediated activation of Ca2+-dependent conductive Cl- transport by shark-derived polyaminosterols, Am J Physiol Regul Integr Comp Physiol. 289(6):R1644-58 (December 2005)
Chernova, MN., Vandorpe, DH., Clark, JS., Alper, SL., Expression of the polycystin-1 C-terminal cytoplasmic tail increases Cl- channel activity in Xenopus oocytes, Kidney Int. 68(2):632-41 (August 2005)
Sherman, T., Chernova, MN., Clark, JS., Jiang, L, Alper, SL., Nehrke, K., The abts and sulp families of anion transporters from Caenorhabditis. elegans, Am J Physiol Cell Physiol. 289(2):C341-51 (August 2005)
Atochin DN, Clark J, Demchenko IT, Moskowitz MA, Huang PL., Rapid cerebral ischemic preconditioning in mice deficient in endothelial and neuronal nitric oxide synthases, Stroke. 34(5):1299-303 (May 2003)
Toh HC., Spitzer TR., Preffer F., Alexander SI., McAfee S., Dombkowski D., Clark JS., Colby C., Saidman S., Sackstein R., Sykes M., Fluctuating lymphocyte chimerism, tolerance and anti-tumor response in a patient with refractory lymphoma receiving nonmyeloablative conditioning and a haploidentical related allogeneic bone marrow transplant, Cytokines, Cellular & Molecular Therapy. 7(2):43-7 (December 2002).
|
